1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 16 to 65 Sponsor: Other Protocol IDs: MCC-14178, NCT00361140
|
|
2.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: UARK 2003-26, NCT00090493
|
|
3.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 4 and over Sponsor: NCI Protocol IDs: RPCI-I-72806, I 72806, NCT00536601
|
|
4.
|
Phase: Phase III Type: Treatment Status: Active Age: Under 75 Sponsor: NCI Protocol IDs: FHCRC-1813.00, 5666, NCT00075478
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: FHCRC-2004.00, 6004, MEDIMMUNE-FHCRC-2004.00, NCT00217438
|
|
6.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2006-05, NCT00573391
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 74 Sponsor: Other Protocol IDs: 2006-15, NCT00574080
|
|
8.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 25009, 59306670 7R01CA115399, NCT00670631
|
|
9.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 26866138 MMY 3021, NCT00722566
|
|
10.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: UARK 2008-01, NCT00734877
|
|
11.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2008_525, MK0683-088, NCT00773747
|
|
12.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI Protocol IDs: FHCRC-1803.00, 5606, NCT00068718
|
|
13.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: H8713, NCT00058825
|
|
14.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CP-101, efficacy, pharmacokinetics, research markers, NCT00086216
|
|
15.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: NCI Protocol IDs: CHNMC-04064, NCT00112827
|
|
16.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: OSU-04100, OSU-2005C0006, NCI-7002, 7002, NCT00112723
|
|
17.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: NCI Protocol IDs: OHSU-HEM-05011-L, OHSU-210, NCT00245037
|
|
18.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Older patients Sponsor: NCI, Other Protocol IDs: BMT124, 75117, BMT124, NCT00185692, NCT00185692
|
|
19.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CPMC-AAAB6443, NCT00334932
|
|
20.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: BMT183, 97115, BMT183, NCT00349778, NCT00349778
|
|
21.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-065, X05175, NCT00369226
|
|
22.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 2006-0803, NCT00410982
|
|
23.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PROTOCOL: IMMU-115-01, NCT00421525
|
|
24.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 04U.115, NCT00429416
|
|
25.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-LS0689, LS0689, MAYO-07-000710, NCT00474929
|